Agilent Technologies Introduces New Column Innovations for Biotherapeutics Development

Agilent Technologies Inc. (NYSE: A) today introduced the AdvanceBio RP-mAb, a reversed-phase column optimized to separate monoclonal antibodies. The AdvanceBio RP-mAb-the latest in a series of products in the AdvanceBio family-is part of Agilent’s extensive R&D effort to support biological research and drug development by increasing the accuracy and productivity of biocolumns technology.

Monoclonal antibodies, or mAbs, are the primary proteins researchers study to develop biotherapeutics, biosimilars and biobetters.

“The Agilent AdvanceBio RP-mAb is the only reversed-phase column optimized specifically for mAbs,” said Anne Jones, Agilent’s vice president of Chemistries. “Its 450Å pore size is optimal for obtaining higher resolution-a vital factor for researchers, as mAbs are notoriously difficult to analyze.”

Like all Agilent’s industry-leading AdvanceBio products, the new column is designed and manufactured solely by Agilent for premium, end-to-end quality control.

AdvanceBio RP-mAb columns leverage Agilent’s Poroshell technology for fast, high-resolution analysis of intact mAbs. The column is 3.5 μm, 450Å superficially porous, and stable to 600 bar. Agilent also offers three chemistries-C8, C4 and unique diphenyl-providing researchers with options for refining their separations.

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of $3.9 billion in fiscal 2013. The company employs about 11,000 people worldwide. Information about Agilent is available at www.agilent.com.